

RECEIVED  
CENTRAL FAX CENTER

SEP 02 2005

Practitioner's Docket No. MPI94-008CP2DV2CN5M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Adams, Julian, et al.		
Application No.:	10/730,231	Group No.:	1626
Filed:	December 8, 2003	Examiner:	Coppins, Janet L.
For:	BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES		

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER (37 C.F.R. SECTION 1.321(b) and (c))

Sir:

MILLENNIUM PHARMACEUTICALS, INC. ("Millennium"), sole owner of the above-identified patent application, hereby disclaims any portion of the term of any patent granted on that application which would extend beyond the expiration of U.S. Patent Nos.:

5,780,454

6,083,903

6,617,317

6,747,150,

RECEIVED  
OIPE/IAP

SEP 06 2005

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☐ deposited with the United States Postal Service in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  
37 C.F.R. SECTION 1.8(a) 37 C.F.R. SECTION 1.10\*

- ☐ with sufficient postage as first class mail.

- ☐ as "Express Mail Post Office to Addressee"  
Mailing Label No.

TRANSMISSION

- ☒ transmitted by facsimile to the Patent and Trademark Office (571-273-8300).

*Paula Swirka*

Signature  
Paula Swirka  
(type or print name of person certifying)

Date: September 2, 2005

\*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

**Practitioner's Docket No. MPI94-008CP2DV2CN5M**

which are also solely owned by Millennium. Any patent granted on the above-identified application shall be enforceable only for and during such period that such patent is commonly owned with U.S. Patent Nos. 5,780,454; 6,083,903; 6,617,317; and 6,747,150. Millennium does not disclaim any portion of the term of such patent which would extend beyond invalidation or other premature termination of enforceability of U.S. Patent Nos. 5,780,454; 6,083,903; 6,617,317; and 6,747,150.

**FEE PAYMENT**


- ☐ Attached is a check in the sum of \$ \_\_\_\_\_ .  
☐ Charge Account 501668 for any fee deficiency.  
☒ Charge Deposit Account 501668 the sum of \$130.00 (37 CFR 1.20(d) and for any fee deficiency that may be due or credit any overpayments associated with this matter.

**A duplicate of this disclaimer is attached.**

September 2, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By

  
Janice M. Klunder

Registration No. 41,121  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-551-3699  
Facsimile - 617-551-8820

BEST AVAILABLE COPY

(Page 2 of 2)

RECEIVED  
CENTRAL FAX CENTER

SEP 02 2005

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

In re application of:	Adams, Julian, et al.		
Application No.:	10/730,231	Group No.:	1626
Filed:	December 8, 2003	Examiner:	Coppins, Janet L.
For:	BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES		

Practitioner's Docket No. (MPI94-008CP2DV2CN5M)

PATENT

## Certificate of Transmission under 37 CFR 1.8

1-571-273-8300

I hereby certify that this correspondence is being facsimile transmitted to the  
United States Patent and Trademark Office

on September 2, 2005

Signature

Paula Swirka

Typed or printed name of person signing Certificate

## Submitted herewith:

This Certificate of Transmission under 37 CFR 1.8  
Terminal Disclaimer (37 CFR 1.321 (b) and (c) (2 pages, in duplicate)

1 page  
4 pages

**Total**    **5 pages**  
(including this cover sheet)

TC/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.